Phio Pharmaceuticals Net Worth
Phio Pharmaceuticals Net Worth Breakdown | PHIO |
Phio Pharmaceuticals Net Worth Analysis
Phio Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Phio Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Phio Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Phio Pharmaceuticals' net worth analysis. One common approach is to calculate Phio Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Phio Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Phio Pharmaceuticals' net worth. This approach calculates the present value of Phio Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Phio Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Phio Pharmaceuticals' net worth. This involves comparing Phio Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Phio Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Phio Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Phio Pharmaceuticals' net worth research are outlined below:
| Phio Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (10.83 M) with loss before overhead, payroll, taxes, and interest of (7.01 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (10.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Dispersyn Gerrit of 68450 shares of Phio Pharmaceuticals subject to Rule 16b-3 |
Phio Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Phio Pharmaceuticals Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Phio Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Phio Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phio Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phio Pharmaceuticals Corp backward and forwards among themselves. Phio Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phio Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nordwand Advisors Llc | 2024-09-30 | 500 | Wells Fargo & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Bank Of Montreal | 2024-06-30 | 0.0 | Bmo Capital Markets Corp. | 2024-06-30 | 0.0 |
Follow Phio Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.02 M.Market Cap |
|
Project Phio Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.40) | (1.33) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.40) | (1.33) |
When accessing Phio Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Phio Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Phio Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Phio Pharmaceuticals' management efficiency
Phio Pharmaceuticals Corp has return on total asset (ROA) of (0.6107) % which means that it has lost $0.6107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2686) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -1.21. In addition to that, Return On Capital Employed is likely to grow to -1.33. At this time, Phio Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 30th of November 2024, Total Current Assets is likely to grow to about 12.1 M, while Non Current Assets Total are likely to drop about 39.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 33.46 | 35.14 | |
| Tangible Book Value Per Share | 33.46 | 35.14 | |
| Enterprise Value Over EBITDA | 0.65 | 0.68 | |
| Price Book Value Ratio | 0.20 | 0.19 | |
| Enterprise Value Multiple | 0.65 | 0.68 | |
| Price Fair Value | 0.20 | 0.19 | |
| Enterprise Value | -7.4 M | -7 M |
The operational strategies employed by Phio Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 172.2001 | Return On Equity (1.27) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phio Pharmaceuticals Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 13th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Phio Pharmaceuticals Earnings per Share Projection vs Actual
Phio Pharmaceuticals Corporate Management
| Jim Cardia | VP Operations | Profile | |
| Caitlin Kontulis | VP Secretary | Profile | |
| Dr MedSc | Interim Director | Profile | |
| Linda Mahoney | Senior Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.81) | Return On Assets (0.61) | Return On Equity (1.27) |
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.